Cell and gene therapies (CGTs) represent a significant advancement in medical treatment, yet their manufacturing and distribution processes are inherently complex and challenging to scale. Unlike traditional pharmaceuticals that can often be produced in bulk, CGTs are typically custom-made with a very limited shelf life. This is particularly true for ex vivo therapies, where living cells are harvested from donors, processed, and then delivered to patients. The entire process involves significant time and distance, necessitating cryogenic freezing to preserve the integrity and function of the cells.
The Importance of Cryogenic Storage
To maintain cell viability, a temperature below the glass transition of water, approximately -135°C, is essential. At this temperature, metabolic activity is halted, preventing degradation. Any warming above this threshold, even briefly, can cause cell damage, compromising treatment efficacy.
Establishing a robust cold chain is critical for timely and high-quality delivery of CGTs. This article explores the challenges in developing such a cold chain and offers strategies to enhance the reproducibility and traceability of CGTs, ultimately improving clinical studies and commercialization efforts.
Risks During Handling and Transport
Once cells are separated from the donor, they are vulnerable to damage. Routine handling, storage, and transport can expose CGT materials to temperatures exceeding the critical threshold, jeopardizing their viability and effectiveness. Given the stark temperature differences between storage and operational environments, even short exposure to ambient conditions can lead to rapid warming and potential harm to cryopreserved materials.
Liquid nitrogen (LN2) is the preferred method for cryogenic storage due to its boiling point of -196°C. Samples can be safely stored in both the liquid and vapor phases of LN2. However, retrieving samples presents its own challenges. When samples are moved from an LN2 freezer to ambient temperatures, they can reach critical warming levels within approximately 90 seconds. This narrow window increases the risk of transient warming events that can significantly compromise cell quality.
Quality Management and Best Practices
To mitigate these risks, a strong quality management system is essential. Facilities utilizing LN2 for cryogenic storage should adhere to best practices set forth by recognized industry authorities. For companies lacking the infrastructure or expertise, collaborating with external partners to store CGT materials can be a viable solution.
The Role of Automation in the Cold Chain
Incorporating automation into the cold chain can greatly enhance reproducibility. Manual retrieval methods expose entire racks of materials to ambient conditions, increasing the risk of damage. Robotics, on the other hand, can retrieve samples at low temperatures without compromising the controlled environment. Automated systems minimize the risk of human error, such as retrieving incorrect materials or mishandling samples, resulting in more consistent performance.
Navigating the Complexity of Advanced Therapies
The production and distribution of ex vivo therapies present unique challenges compared to traditional pharmaceuticals. For instance, autologous therapies like CAR-T involve the patient both as a donor and a recipient, complicating the tracking process. Ensuring end-to-end visibility—from the collection of raw materials to processing and eventual administration—is vital for patient safety and the success of the therapy. This necessitates meticulous documentation of both chain of identity and chain of custody to comply with regulatory standards.
Leveraging Third-Party Partnerships
Given the complexities involved in transportation logistics, many CGT companies opt to partner with specialized third-party vendors. These vendors possess the expertise to navigate the intricacies of tracking and delivering materials, thereby reducing risks and improving supply chain efficiency.
Streamlining Processes with Automated Systems
Automated LN2 freezers not only enhance tracking capabilities but also provide real-time visibility and comprehensive event logging. By integrating with laboratory information management systems (LIMS), these systems simplify the processes of sample handling and tracking. Automated scanning of barcode-labeled materials ensures accurate logging of transactions, facilitating compliance and traceability.
Conclusion
The potential of advanced therapies to address previously untreatable diseases is immense, but their delicate and custom nature poses significant hurdles for large-scale clinical and commercial applications. To protect the value of critical materials throughout the cold chain, CGT companies must focus on enhancing reproducibility and traceability. By embracing automation and collaborating with specialized partners, these companies can effectively mitigate risks associated with the manufacturing and distribution of cell and gene therapies.
- Key Takeaways:
- Cryogenic storage is crucial to maintaining cell viability in CGTs.
- Automation can significantly reduce risks associated with human error in cold chain management.
- Thorough documentation of chain of identity and custody is vital for compliance and patient safety.
- Collaborating with specialized third parties can streamline logistics and improve efficiency.
- Real-time tracking and automated systems enhance reproducibility and accuracy in CGT handling.
Read more → www.pharmaceuticalcommerce.com